Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.97 EUR | -1.66% | +0.34% | -36.40% |
May. 02 | Biotalys Starts Field Trials for Second Biofungicide | CI |
Apr. 30 | Biotalys Announces Board and Committee Changes | CI |
Sales 2024 * | 3M 3.25M | Sales 2025 * | 3M 3.25M | Capitalization | 95.51M 104M |
---|---|---|---|---|---|
Net income 2024 * | -11M -11.93M | Net income 2025 * | -12M -13.01M | EV / Sales 2024 * | 30.4 x |
Net cash position 2024 * | 4.4M 4.77M | Net Debt 2025 * | 9M 9.76M | EV / Sales 2025 * | 34.8 x |
P/E ratio 2024 * |
-6.91
x | P/E ratio 2025 * |
-2.48
x | Employees | 75 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.77% |
Latest transcript on Biotalys NV
1 day | -1.66% | ||
1 week | +0.34% | ||
1 month | -4.19% | ||
3 months | -18.63% | ||
6 months | -2.30% | ||
Current year | -36.40% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin R. Helash
CEO | Chief Executive Officer | 59 | Nov. 30 |
Douglas Minder
DFI | Director of Finance/CFO | - | 20-12-31 |
Carlo Boutton
CTO | Chief Tech/Sci/R&D Officer | - | 22-05-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 62 | 12-12-31 | |
Simon Moroney
CHM | Chairman | 65 | 21-03-31 |
Johan Cardoen
BRD | Director/Board Member | 65 | 12-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 2.97 | -1.66% | 23,809 |
24-05-30 | 3.02 | +0.67% | 12,459 |
24-05-29 | 3 | -.--% | 983 |
24-05-28 | 3 | -.--% | 7,874 |
24-05-27 | 3 | +1.35% | 1,686 |
Real-time Euronext Bruxelles, May 31, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-36.40% | 104M | |
-4.73% | 7B | |
+8.44% | 3.19B | |
+9.43% | 861M | |
-2.96% | 360M | |
+5.08% | 273M | |
+131.82% | 56.08M |
- Stock Market
- Equities
- BTLS Stock